The FDA approved the drug maker's application for Albutropin, which analyst Carolyn Pratt says a long-acting form of human growth hormone -- meaning less frequent administration. Human Genome plans to begin with clinical studies in growth hormone deficient adults, and also is planning future trials in children. She says Human Genome differentiates itself from other gene companies in that it has put a continuous stream of drug candidates into clinical trials. She thinks Albutropin provides additional proof that Human Genome can continue to a build large, diverse pipeline. Pratt expects to hear more at Human Genome's investor meeting on Wednesday.